恒瑞医药：HRS-6209胶囊、HRS-2189片获临床试验批准

Core Insights - The company and its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., have received approval from the National Medical Products Administration for clinical trials of HRS-6209 capsules and HRS-2189 tablets [1] Group 1: Product Development - HRS-6209 is a novel selective CDK4 inhibitor intended for the treatment of advanced malignant solid tumors [1] - HRS-2189 is a new KAT6 inhibitor aimed at treating advanced malignant tumors [1] Group 2: Research and Development Investment - Cumulative R&D investment for the HRS-6209 project is approximately 80.37 million yuan [1] - Cumulative R&D investment for the HRS-2189 project is around 49 million yuan [1]